Czech Republic

EQS-News: STRABAG SE Trading Statement 9M/2023: higher output forecast for 2023

Retrieved on: 
Monday, December 25, 2023

The publicly listed European technology group for construction services STRABAG SE today announced its figures for the first nine months of 2023.

Key Points: 
  • The publicly listed European technology group for construction services STRABAG SE today announced its figures for the first nine months of 2023.
  • “In view of the continued growth of the order backlog and the significant increase in output in the first nine months, we are raising our output forecast for 2023 from € 18.6 billion to around € 18.9 billion.
  • Business development in transportation infrastructure construction remains solid,” explains Klemens Haselsteiner, CEO of STRABAG SE.
  • STRABAG SE generated an output volume of € 13.6 billion in the first nine months of 2023, which corresponds to an increase of 8% compared to the same period of the previous year.

EQS-News: CPI PROPERTY GROUP – Sale of two Retail Properties to IMMOFINANZ AG

Retrieved on: 
Friday, December 22, 2023

CPI PROPERTY GROUP (“CPIPG” or the “Company”) is pleased to announce the sale of the Olympia Pilsen shopping centre and a retail park in the Czech Republic to IMMOFINANZ.

Key Points: 
  • CPI PROPERTY GROUP (“CPIPG” or the “Company”) is pleased to announce the sale of the Olympia Pilsen shopping centre and a retail park in the Czech Republic to IMMOFINANZ.
  • The Olympia Pilsen Shopping Center is located on the southeast border of Pilsen and has more than 120 shops on 41,000 m² of space.
  • The transaction technically qualifies as a related party transaction because CPIPG consolidates IMMOFINANZ.
  • As a related party disposal, this sale is not included in CPIPG’s €2 billion external disposal pipeline.

Endexx Initiates TPD Registration in Europe

Retrieved on: 
Tuesday, November 14, 2023

CAVE CREEK, AZ, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Endexx® Corporation (OTCQB: EDXC), a provider of innovative plant-based wellness and nutritional products, today announced that its HYLA division has completed preliminary review of its premium vegan formulated traditional e-cigarette products. Hyla is filing its TPD application in Europe. TPD is (The “Tobacco Products Directive” (2014/40/EU) which aims to improve the functioning of the internal market for tobacco and related products, while ensuring a high level of health protection for European citizens.)

Key Points: 
  • Hyla is filing its TPD application in Europe.
  • The demand for the HYLA non-nicotine products is quickly gaining market share in the initial markets in Europe.
  • The TPD registration completely opens the European market to all HYLA’s products.
  • “This registration process helps secure the success of our long- term target of being a dominant player in the international age-restricted CPG markets.”

Euro Manganese Produces High-Purity Manganese Sulphate from Chvaletice Demonstration Plant

Retrieved on: 
Monday, November 13, 2023

Euro Manganese’s Demonstration Plant is an essential step in reducing risk in the Company’s flowsheet (see Figure 1).

Key Points: 
  • Euro Manganese’s Demonstration Plant is an essential step in reducing risk in the Company’s flowsheet (see Figure 1).
  • The Demonstration Plant has already provided many learning opportunities and lessons that are being fed into the engineering process for the commercial plant.
  • Dr. Matthew James, President & CEO of Euro Manganese, commented:
    “Producing high-purity manganese sulphate from our Demonstration Plant is a significant milestone for the Company.
  • Euro Manganese continues to demonstrate it is a leader in developing western high-purity manganese processing capacity.

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023

WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA; ATI-450-RA-202).

Key Points: 
  • The primary efficacy endpoint is the proportion of patients achieving an ACR20 response following 12 weeks of treatment.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris’ ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
  • “We are deeply disappointed with the results of this trial and for patients suffering from rheumatoid arthritis.
  • Aclaris is supporting Washington University in a first-in-human investigator-initiated Phase 1a trial of ATI-2231 in patients with advanced solid tumor malignancies.

Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis

Retrieved on: 
Monday, November 13, 2023

A 3-month treatment duration is considerably shorter than for other topical agents used for onychomycosis (~11 months).

Key Points: 
  • A 3-month treatment duration is considerably shorter than for other topical agents used for onychomycosis (~11 months).
  • The primary objective was an assessment of early clinical and/or mycological activity of BB2603-10 versus vehicle at Week 16, 1 month after end of treatment.
  • Secondary endpoints were assessed at the end of the trial at Week 52, 9 months after the end of the 3-month treatment period.
  • "We are excited to announce the successful completion of our Phase 2b trial, which delivered remarkable treatment outcomes following just three months of dosing.

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression

Retrieved on: 
Monday, November 13, 2023

MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today favorable results from its head-to-head trial with KET01, the Company’s proprietary lead asset, versus SPRAVATO®, the FDA-approved intranasal spray for patients with Treatment-Resistant Depression (TRD). KET01 is an IP protected oral prolonged-release formulation of ketamine and is being studied in patients with TRD. Due to its unique metabolite profile, the incidence of dissociation with KET01 was very low and statistically significantly lower relative to SPRAVATO®, pointing to a clinically meaningful difference, which could offer the potential for a safe at-home unsupervised administration. During the summer Ketabon also released data from its Phase 2 KET01-02 trial with KET01, which demonstrated rapid and durable improvements in depressive symptoms in TRD. 

Key Points: 
  • KET01 is an IP protected oral prolonged-release formulation of ketamine and is being studied in patients with TRD.
  • During the summer Ketabon also released data from its Phase 2 KET01-02 trial with KET01, which demonstrated rapid and durable improvements in depressive symptoms in TRD.
  • Only minimal signs of dissociative symptoms were detected by the CADSS scale, and no changes in cardiovascular parameters were detected.
  • “Data continues to suggest rapid and clinically relevant reduction of depressive symptoms after oral treatment with 240 mg/day of KET01.

Hurco Companies, Inc. Announces Quarterly Cash Dividend

Retrieved on: 
Friday, November 10, 2023

The dividend will be paid on January 16, 2024, to shareholders of record as of the close of business on January 2, 2024.

Key Points: 
  • The dividend will be paid on January 16, 2024, to shareholders of record as of the close of business on January 2, 2024.
  • Future declarations of dividends are subject to approval of the Board of Directors and may be adjusted as business needs or market conditions change.
  • Hurco Companies, Inc. is an international, industrial technology company that sells its three brands of computer numeric control (“CNC”) machine tools to the worldwide metal cutting and metal forming industry.
  • Two of the Company’s brands of machine tools, Hurco and Milltronics, are equipped with interactive controls that include software that is proprietary to each respective brand.

ServiceNow to Acquire Task Mining Company UltimateSuite to Enhance Process Mining and Intelligent Automation on the Now Platform

Retrieved on: 
Monday, December 18, 2023

ServiceNow (NYSE: NOW), the leading digital workflow company making the world work better for everyone, today announced it has signed an agreement to acquire task mining company UltimateSuite to enhance process mining and intelligent automation across the Now Platform.

Key Points: 
  • ServiceNow (NYSE: NOW), the leading digital workflow company making the world work better for everyone, today announced it has signed an agreement to acquire task mining company UltimateSuite to enhance process mining and intelligent automation across the Now Platform.
  • Through this acquisition, ServiceNow continues to bolster its automation and artificial intelligence (AI) capabilities to help customers identify process bottlenecks and drive stronger operational efficiencies.
  • UltimateSuite's task mining technology provides actionable insights to streamline repetitive work and identify automation opportunities, a core piece of process mining.
  • With predictive analysis and actionable prompts, UltimateSuite provides operational intelligence that enables customers to accelerate digital business transformation and enhance employee experiences.

Tyvak International Completes Test Readiness Review of the Milani Nano Satellite

Retrieved on: 
Friday, December 15, 2023

Tyvak International, European leader in small satellite solutions, today announced together with its project partners the successful achievement of Test Readiness Review of the Milani spacecraft.

Key Points: 
  • Tyvak International, European leader in small satellite solutions, today announced together with its project partners the successful achievement of Test Readiness Review of the Milani spacecraft.
  • A critical component of the Hera planetary defense mission, Milani will be the European Space Agency’s (ESA) first deep-space nanosatellite.
  • In this exploration, Tyvak International is joined by an excellent consortium of European industries and research centers from Finland, Czech Republic, and Italy.
  • “Terran Orbital is proud of Tyvak International’s successful achievement of the Test Readiness Review,” said Terran Orbital Co-Founder, Chairman, and Chief Executive Officer Marc Bell.